Skip to main content

Our Patients

Our Commitment to Patients

Equillium is dedicated to finding new treatments to dramatically improve the lives of patients with diseases where treatment options are limited or not available.

Disease Areas

Equillium's novel immunomodulatory assets target immuno-inflammatory pathways.

Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells, is currently in a Phase 3 study for patients with acute graft-versus-host disease (aGVHD) and is in a Phase 1b study for patients with lupus/lupus nephritis.

EQ101, a first-in-class tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15, is Phase 2 ready and expected to begin enrolling patients in an alopecia areata study in the second half of 2022.

EQ102, a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Phase 1 study to include patients with celiac disease in the second half of 2022.

Graft-Versus-Host Disease

Hematopoietic stem cell transplant (HSCT) provides a potentially curative option for some types of cancer, but it comes with the risk of GVHD. GVHD occurs when the transplanted immune system attacks the recipient’s body and is the leading cause of non-cancer death in stem cell transplant recipients.

Learn About Graft-Versus-Host Desease

Lupus Nephritis

Lupus nephritis is among the most serious complications of systemic lupus erythematosus (SLE), occurring in 30 – 60% of individuals with SLE. In lupus nephritis, the body’s own immune system attacks the kidneys, causing inflammation and significantly reducing kidney function over time.

Learn About Lupus Nephritis

Advocacy Resources

Lupus Nephritis

  • Lupus Research Alliance

    • The Lupus Research Alliance is ready to conquer lupus. Breakthroughs in research have unlocked the potential to turn the very complexity of lupus — its heterogeneity — into the cure.

  • Lupus Foundation of America

    • The Lupus Foundation of America’s mission is to improve the quality of life for all people affected by lupus through programs of research, education, support, and advocacy. We are focused on achieving the following disease-specific outcomes.

  • Lupus and Allied Diseases Association

    • The mission of Lupus and Allied Diseases Association, Inc., is to advocate for those affected by lupus and allied diseases through awareness and research program initiatives to improve quality of life.

Graft-Versus-Host Disease

  • Be The Match

    • Saving Lives Through Cellular Therapy

  • BMT InfoNet

    • Blood & Marrow Transplant Information Network (BMT InfoNet) is a leading advocacy organization for bone marrow, stem cell and cord blood transplant patients.

  • nbmtLINK

    • Our mission is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

  • Meredith Cowden Foundation

    • Our mission is to increase the number of leukemia survivors, to raise awareness of the blood cancers and help people living with the treatment of them, to improve the post-transplant quality of life for bone marrow transplant recipients, and to support the Leukemia & Lymphoma Society.